7 results about "Yellow fever" patented technology

The invention discloses a chikungunya virus envelope E2 protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

The invention discloses a chikungunya virus monoclonal antibody and application thereof in preparation of preventive and therapeutic antibody drugs, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

This disclosure relates to stabilizers for compositions comprising live-attenuated flaviviruses, methods for stabilizing live-attenuated flaviviruses, and stabilized live-attenuated flavivirus vaccine compositions.

The invention discloses a chikungunya virus envelope E2 protein monoclonal antibody and application of the chikungunya virus envelope E2 protein monoclonal antibody in preparation of preventive and therapeutic antibody drugs, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

The present application provides the use of MIR2911 in the preparation of drugs against yellow fever virus YFV. Compared with the prior art, the present application has the following advantages: the application provided by the present application innovatively proposes a strategy for inhibiting YFV replication using MIR2911 small nucleic acid drugs, which can specifically target multiple genes of YFV and more effectively inhibit YFV replication than ribavirin; cell experiments have verified the inhibitory effects at the mRNA, protein and virus particle levels. The RNA sequence that ultimately exerts the effect is encapsulated and transported by endogenous exosomes, and there is no immune response. There is no need to verify the safety of exosomes, and it can also compensate for individual differences in oral MIR2911. Compared with protein and peptide drugs with a single target on the market, it is low-cost and more efficient.

The present disclosure is based, at least in part, on the discovery of antibodies that specifically bind YFV and / or neutralize the virus. Compositions and methods related to such antibodies or antigen-binding portions thereof are provided.

The present application belongs to the technical field of economic crop biological prevention and control, and provides a plant source attractant for Empoasca vitis and application thereof. The plant source attractant for Empoasca vitis is composed of farnesene, linalool and leaf alcohol. The attractant is placed at tea shoots in early spring and early autumn when adult insects occur, and can be prepared into a lure core and other preparation forms. In order to achieve better trapping effect, the attractant can be used in combination with a yellow yellow fever mosquito plate. The attractant is of plant source and is safe to the environment, has the characteristics of high efficiency, greenness and convenience, and has a wide industrialization prospect.